X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support Dyadic's in microbial platforms for flexible-scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Recipient: Dyadic International, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 21, 2024
Details:
The BriLife vaccine has unique potential to combat emerging Covid variants and especially to achieve mucosal immunity that has not previously been achieved by mRNA vaccines.
Lead Product(s): Recombinant Vesicular Stomatitis Virus Delta G
Therapeutic Area: Infections and Infectious Diseases Product Name: BriLife
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Recipient: NRx Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2022
Details:
IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of the Wuhan wild-type SARS-CoV-2 virus. Preclinical and phase 1/2 trials have demonstrated no safety signals of concern and have further demonstrated immunologic response.
Lead Product(s): rVSV-SARS-CoV-2-S Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: IIBR-100
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: NRx Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
Analysis of Blood Samples from Patients who Responded to the BriLife vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original “Wild-Type” Virus.
Lead Product(s): Recombinant Vesicular Stomatitis Virus ΔG
Therapeutic Area: Infections and Infectious Diseases Product Name: BriLife
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Recipient: NRx Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 26, 2021
Details:
Participants who received lower doses of the BriLife vaccine, rVSV-SARS-CoV-2-S vaccine, have been advised to get a booster vaccination with Pfizer or Moderna shots, as those lower dosages do not appear to offer sufficient long-term protection.
Lead Product(s): rVSV-SARS-CoV-2-S Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: IIBR-100
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Recipient: NRx Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2021
Details:
The Israel Institute for Biological Research began animal trials for its “BriLife” vaccine in March. The vaccine, the ministry said, has already tested well on a number of animal models & the IIBR has produced more than 25,000 doses for I & II phases of the clinical trials.
Lead Product(s): Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
A source familiar with IIBR activities told Reuters that trials were already under way on rodents. The source declined to identify the kind of rodent.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
Details:
The research collaboration combines IIBR's renowned scientific capabilities and cGMP facilities with Dyadic's patented and proprietary C1 gene expression platform.
Lead Product(s): rVaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Dyadic International, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
